CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Co-Diagnostics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.67+0.01 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $2.87M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$9.0600 (−93.15%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Co-Diagnostics, Inc. saw revenue fall 28.1% to $721.39K over the twelve months to Jun 30, 2026. Free cash flow was -$27.47M.
Revenue
$721.39K
-28.1% vs. a year earlier
Operating income
-$48.96M
TTM Q2 2026
Free cash flow
-$27.47M
TTM Q2 2026
EPS, diluted
-$23.99
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.87M
- P/E ratio
- –
- Price to sales
- 3.98
- Price to book
- 0.23
- Dividend yield
- –
- Free cash flow yield
- -957.01%
Fundamentals
- Revenue
- $721.39K
- Net income
- -$47.06M
- EPS, diluted
- -$23.99
- Free cash flow
- -$27.47M
- Book value per share
- $2.95
- Diluted shares
- 4M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$721.39K-28.1% YoY
Gross profit
$313.64K-21.1% YoY
Operating income
-$48.96M
Net income
-$47.06M
EPS, diluted
-$23.99
Free cash flow
-$27.47M
Reported periodTrailing twelve months